Q-PRAVASTATIN TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

PRAVASTATIN SODIUM

Saadav alates:

QD PHARMACEUTICALS ULC

ATC kood:

C10AA03

INN (Rahvusvaheline Nimetus):

PRAVASTATIN

Annus:

40MG

Ravimvorm:

TABLET

Koostis:

PRAVASTATIN SODIUM 40MG

Manustamisviis:

ORAL

Ühikuid pakis:

30/100

Retsepti tüüp:

Prescription

Terapeutiline ala:

HMG-COA REDUCTASE INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0122563003; AHFS:

Volitamisolek:

CANCELLED PRE MARKET

Loa andmise kuupäev:

2015-08-21

Toote omadused

_Page 1 of _
_47_
PRODUCT MONOGRAPH
PR
Q-PRAVASTATIN
pravastatin sodium tablets
10 mg, 20 mg and 40 mg
USP
Lipid Metabolism Regulator
QD Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Submission Control Number: 164225
Date of Revision: May 31, 2013
_Page 2 of _
_47_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION .................................................... 3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
5
WARNINGS AND PRECAUTIONS
.................................................................................
6
ADVERSE REACTIONS
.................................................................................................
11
DRUG INTERACTIONS
.................................................................................................
16
DOSAGE AND ADMINISTRATION
.............................................................................
18
OVERDOSAGE
................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 19
STORAGE AND STABILITY
.........................................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 22
PART II: SCIENTIFIC INFORMATION ............................................................................
24
PHARMACEUTICAL INFORMATION
.........................................................................
24
CLINICAL TRIALS
.........................................................................................................
25
DETAILED PHARMACOLOGY
....................................................................................
32